科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background @@@ Salvia Miltiorrhiza Depside Salt for Infusion (SMDS) is made of a group of highly purified listed drugs. However, its safety data is still reported limitedly. Compared with the clinical trials, its safety in the real world setting is barely assessed. @@@ Objective @@@ To investigate the safety issues, including adverse events (AEs), adverse events related to SMDS (ADEs), and adverse drug reactions (ADRs) of the SMDS in the real world clinical practice. @@@ Methods @@@ This is a prospective, multicenter, pharmacist-led, cohort study in the real world setting. Consecutive patients prescribed with SMDS were all included in 36 sites. Pharmacists were well trained to standardized collect the patients information, including demographics, medical history, prescribing patterns of SMDS, combined medications, adverse events, laboratory investigations, outcomes of the treatment when discharge, and interventions by pharmacists. Adverse events and adverse drug reactions were collected in details. Multivariate possion regression analysis was applied to identify risk factors associated with ADEs using the significance level (a) 0.05. ClinicalTrials. gov Identifier: NCT01872520. @@@ Results @@@ Thirty six hospitals were participated in the study and 30180 consecutive inpatients were included. The median age was 62 (interquartile range [IQR], 50-73) years, and male was 17384 (57.60%) among the 30180 patients. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. There were 9 kinds of new ADEs which werenot on the approved label found in the present study. According to the multivariate analysis, male ( RR = 1.381, P = 0.009, 95% CI [ 1.085 similar to 1.759]), more concomitant medications ( RR = 1.049, P< 0.001, 95% CI [ 1.041 similar to 1.057]), longer duration of SMDS therapy ( RR = 1.027, P< 0.001, 95% CI [ 1.013 similar to 1.041]), higher drug concentration ( RR = 1.003, P = 0.014, 95% CI [ 1.001 similar to 1.006]), and resolvent unapproved ( RR = 1.900, P = 0.002, 95% CI [ 1.260 similar to 2.866]) were the independent risk factors of the ADEs. Moreover, following the approved indication ( RR = 0.655, P< 0.001, 95% CI [ 0.532 similar to 0.807]) was associated with lower incidence of ADEs. @@@ Conclusions @@@ SMDS was well tolerated in the general population. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. Several risk factors of its ADEs have been identified. It is recommended to follow the instructions when prescribing and administrating SMDS in the real world clinical practice.
- 出版日期2017-1-26
- 单位北京大学
